Announcement • May 23
Moberg Pharma AB (Publ) Approves the Election of Board Members On May 21, 2026. Moberg Pharma AB (publ) held its Annual General Meeting. The Annual General Meeting resolved, in accordance with the proposal of the shareholder Noster Capital Master Fund Limited ("Noster Capital"), on election of Lars Johansson, Jack Bradley and Daniel Kaufman as board members, all for the period until the end of the next Annual General Meeting. Lars Johansson was elected, in accordance with the proposal of both the Nomination Committee and Noster Capital, as the new Chairman of the Board for the period until the end of the next Annual General Meeting. Lars Johansson, born 1966, has over 30 years of experience in pharmaceuticals and medtech. Lars Johansson has held leading roles within the J&J Group with increasing business area responsibility, including as CEO of the Nordic operations (Johnson & Johnson AB 2011-2019, and Janssen AB 2019-2021). Lars Johansson has also held board positions in Schain Research AB, ProstaLund AB, RLS AB, and Läkemedelsindustriföreningen (the Swedish Association of the Pharmaceutical Industry). Lars Johansson holds a master's degree in business administration from Växjö University. Lars Johansson is currently a board member of Ciencia Research and Carponovum AB. Lars Johansson holds no shares in the Company and is independent in relation to the Company, its management, and major shareholders.Jack Bradley, born 1991, has more than a decade of experience in the investment management business. He joined Noster Capital in 2014, and became a Partner and Head of Research in 2017 covering a broad geographical and market-cap investment universe, frequently giving input to company management teams on investor communication and investor relations strategy. He holds a degree in modern history from the University of Oxford. He is a resident of Norway and a British Citizen. Jack Bradley holds no shares in the Company, but Noster Capital (where he is a Partner) holds 3 055 423 shares in the Company. Jack Bradley is independent in relation to the Company, its management, and major shareholders.Daniel Kaufman, born 1968, has been a serial entrepreneur for the past 35 years, starting over a dozen companies, mostly in the technology sector. In the past 6 years, he shifted his focus to investing in public companies, with a focus on small cap value, and a recent large concentration in healthcare. Over these 6 years, his investment returns have exceeded 50% annually. He currently holds 5%+ positions in Harrow Inc. (HROW), Delcath Systems Inc. (DCTH) and Abeona Therapeutics (ABEO). Daniel Kaufman graduated from Williams College with a degree in political economy. Daniel Kaufman holds 1 409 456 shares in the Company and is independent in relation to the Company, its management, and major shareholders. Announcement • Mar 13
Moberg Pharma AB Secures Additional Terbinafine Supplier For Mob-015 Moberg Pharma AB announced that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed. As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient. Announcement • Oct 31
Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026 Moberg Pharma AB (publ), Annual General Meeting, May 21, 2026. Announcement • Sep 30
Moberg Pharma AB (publ) Approves Board Elections Moberg Pharma AB (publ) at its Extraordinary General Meeting held on September 29, 2025 approved the election of Fredrik Blom and Mona Zhang as new members of the Board of Directors for the period until the end of the next Annual General Meeting. Thus, the Board of Directors of the Company will, for the period until the next Annual General Meeting, consist of Jonas Ekblom (chairman of the board of directors), Nikolaj Sörensen, Isabelle Ducellier, Otto Skolling, Richard Ding, Fredrik Blom and Mona Zhang.Mona Zhang was born in 1981 and holds an MBA from Rotman and a bachelor's degree in electrical engineering from Beijing Institute of Technology. Mona Zhang has more than 15 years of experience in global investment management and corporate governance. Mona is the Founder and Managing Partner of Trunity Partners Ltd., a portfolio management firm registered with the Ontario Securities Commission in Canada, where she is responsible for capital allocation, operations, and compliance. Previously, she worked at Mackenzie Investments as a Portfolio Manager on the Global Equity and Income Team, focusing on investment research, portfolio construction, and risk oversight. Earlier in her career, she was with Burgundy Asset Management, specializing in international equity analysis. Today, Mona serves on the Boards of the Canadian Business History Association and the International Agama Zen Practice Centre. She is also a guest lecturer at the Rotman School of Management, University of Toronto. She is a CFA charterholder. Mona holds no shares in the Company as of the day of this notice and is independent in relation to the Company, its management and major shareholders.Fredrik Blom was born in 1970 and holds a master's degree in financial economics from Stockholm University. Throughout his professional career, Fredrik has primarily worked in sales, often within entrepreneurially driven companies. He has co-founded several companies, one of them is Svenska Studenthus, a real estate company focused on rental and student housing, which merged with K2A Fastigheter prior to the company's IPO on Nasdaq Stockholm in 2019. Fredrik has extensive experience in starting companies and developing their initial cash flows. Other companies Fredrik has co-founded and served on the board of include Jeff Fastigheter and RAW Properties. Fredrik holds 926,000 shares in the Company, directly and indirectly, as of the day of this notice. Fredrik is independent in relation to the Company, its management and major shareholders. Announcement • Jun 25
Moberg Pharma AB (Publ) Announces Management Changes Moberg Pharma AB (publ) announced that in connection with the reorganization, Anders Bröijersén, Chief Medical Officer, and Robert Ehrl, Head of Supply, are leaving Moberg Pharma and the management team. Going forward, supply is incorporated into Christina Erixon's existing area of responsibility. The company's medical expertise is secured through consultants. Following these changes, Moberg Pharma's management team consists of Anna Ljung, Mark Beveridge, Annica Magnusson, and Christina Erixon. Announcement • Dec 18
Moberg Pharma AB (Publ) Secures New Terbinafine Supplier Moberg Pharma AB (publ) announces that a new terbinafine supplier has been secured for MOB-015 (drug for nail fungus). As a result, terbinafine availability is no longer a limiting factor for the company's launch plans.
Over the past year, Moberg Pharma qualified a new terbinafine manufacturer with an authorized EU Certificate of Suitability (CEP) now available for MOB-015. Three product batches have been produced using terbinafine from the new supplier where available stability data confirm the shelf-life profile of MOB-015. The status is unchanged for the previously communicated approval process regarding the first additional terbinafine supplier, submitted in April. Moberg Pharma has earlier responded to all questions received from the Medical Products Agency and awaits the agency´s decision. As a result, Moberg Pharma expects to have several alternate terbinafine suppliers secured in the near future. Each of these suppliers has the capacity to meet the company's global terbinafine demand. Announcement • Nov 08
Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025 Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025. Announcement • Oct 11
Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025 Moberg Pharma AB (publ) announced that they will report fiscal year 2024 results on Feb 11, 2025 Announcement • Sep 13
Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail Fungus Moberg Pharma AB (publ) announced that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015 against nail fungus. The number of patients who have achieved clinical cure in this blinded subset of patients is lower than the company's expectations, which necessitates that Moberg Pharma inform the market about this fact. The North American Phase 3 study is ongoing at 33 study centers in the US and Canada, including a total of 384 patients. The study constitutes an essential part of the clinical data required for the registration and commercialization of MOB-015 in the US and differs from previous studies with MOB-015, which is the basis for drug approval in 13 EU countries, by reducing the dosage - 8 weeks daily dosing followed by weekly maintenance treatment for 40 weeks, compared to daily dosing throughout the entire treatment period. In the process of preparing the database for upcoming topline data, the company has received information regarding clinical cure in a subset of patients in the study. Clinical cure is one of three parameters that together constitute the study's primary treatment goal, complete cure. All three parameters; clinical cure, negative fungal culture, and negative microscopy, need to be met for a patient to be considered completely cured. No information has been obtained about the other study parameters included in complete cure. The information obtained is blinded; no information has been received regarding which patient received active treatment or how many patients in the data subset received active treatment (patients in the study are randomized 2:1 to treatment with MOB-015 and vehicle). The total number of patients who have achieved clinical cure in this subset of patients is lower than the company's expectations, and Moberg Pharma assesses that the risk of not being able to commercialize the product in the US based on this study has significantly increased, which requires the company to inform the market of this fact. It is an absolute priority to protect the integrity of the study data, both as not to undermine the possibilities of using study results in discussions with regulatory authorities, and as there are patients with ongoing treatment in the study. Moberg Pharma will not speculate on possible outcomes or what this means for the future potential of MOB-015 and will await topline results to avoid drawing premature conclusions. Announcement • May 16
Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board Member Moberg Pharma AB (publ) at its Annual General Meeting held on May 14, 2024, approved the election of Jonas Ekblom as board member for a period until the end of the next Annual General Meeting. Announcement • May 08
Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure Moberg Pharma AB announced that MOB-015 has received national approvals for all countries included in the decentralized procedure. MOB-015 is thus approved for the treatment of mild to moderate fungal infections of the nails in adults in 13 European countries. National approvals follow the completion of the decentralized procedure with a positive result where MOB-015 is recommended for approval in 13 European countries. The following EU countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. MOB-015 can be obtained with a prescription (Rx) in the Czech Republic, Denmark, Finland, France, Ireland and Spain, while it's approved as a non-prescription medicinal product, i.e. over-the-counter (OTC) in Austria, Belgium, Hungary, Italy, the Netherlands, Norway and Sweden. Breakeven Date Change • Mar 28
Forecast to breakeven in 2026 The analyst covering Moberg Pharma expects the company to break even for the first time. New forecast suggests the company will make a profit of kr5.00m in 2026. Average annual earnings growth of 48% is required to achieve expected profit on schedule. Board Change • Mar 28
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 02
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Feb 07
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Jan 08
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Dec 12
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • Nov 09
Moberg Pharma Announces Leadership Changes Moberg Pharma AB is strengthening its organization following market approval earlier this year and in preparation for the upcoming launch. The management team is welcoming two new members, Christina Erixon, Head of Pharmaceutical Development & Operations, who is replacing Agneta Larhed, and Robert Ehrl, Head of Supply, who is taking over from Jesper Lind. Both roles have been expanded from part-time consultants to full-time positions. Agneta Larhed is leaving the executive team but will remain a part-time consultant to the company with unchanged scope. Jesper Lind will also remain as a consultant to the company for a period. Christina Erixon has a broad experience of development, regulatory and quality within the pharmaceutical industry. Dr. Erixon has held leading positions within the pharmaceutical industry and at regulatory authorities, including roles as the manager of clinical trials at the Swedish Medical Products Agency, senior product developer at AstraZeneca, business manager and associate director for Pharmaceutical Development at APL, and most recently as the director of Drug Development at SDS Life Science. Dr. Erixon is a pharmacist with a doctoral degree in pharmaceutics from Uppsala University. Robert Ehrl holds a Ph.D. in organic chemist with over 20 years of experience in the pharmaceutical industry. He has held leadership positions at AstraZeneca and Valneva Sweden AB, primarily in process development, supply, and manufacturing. Dr. Ehrl has worked with both small molecule and biological drugs/vaccines, from active pharmaceutical ingredient (API) to final packed product. Announcement • Oct 19
Moberg Pharma AB (publ) Appoints Nomination Committee Moberg Pharma AB (publ) appointed nomination committee. It comprises of Gillis Cullin, appointed by Östersjöstiftelsen, Ida Marie Lindberg, appointed by Kjelsmark Holding, Kerstin Valinder Strinnholm, Chairman of the Board. Announcement • Oct 06
Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America Moberg Pharma AB has completed the recruitment of 384 patients with onychomycosis (nail fungus) for the ongoing MOB-015 phase 3 study in North America. The aim is to provide a pivotal part of the clinical data set for registration and commercialization of MOB-015 in the U.S. Topline results are expected in January 2025. The enrollment to the North American study has now been completed with 384 patients randomized at 33 sites in the U.S. and Canada. Topline results are expected in January 2025. The patients are evaluated over 52 weeks and the primary endpoint is the proportion of subjects achieving complete cure of their target nail. The study design builds on the experience gained from the previous Phase 3 studies. Moberg Pharma cooperate with the same CRO, lead investigator and successful sites from the previous North American study. The purpose of the study is to facilitate market approval in the US as well as strengthen the product's clinical evidence and marketing claims globally. New Risk • Aug 13
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: kr97.8m (US$9.03m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 43% per year for the foreseeable future. Revenue is less than US$1m (kr207k revenue, or US$19k). Market cap is less than US$10m (kr97.8m market cap, or US$9.03m). Announcement • Aug 05
Moberg Pharma AB (publ) Announces National Approval for MOB-015 in Sweden Moberg Pharma AB announced that MOB-015 has received national approval for the company's home market, Sweden, for the treatment of mild to moderate fungal infections of the nails in adults. This is the second country to grant national approval for MOB-015, following the approval in Ireland announced July 31st, and Sweden is the first country where MOB-015 has been approved for over-the-counter (OTC) use. Grant of market authorization in Sweden is significant as commercialization rollout is planned to start in home market. The company will initiate the launch as quickly as possible and expect to initiate launch preparations in Sweden before the end of the year. National approvals follow the completion of the decentralized procedure with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries. The following countries are included: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Currently, national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable, is ongoing. National approvals are expected to occur in the coming months and timelines may vary between countries. Announcement • Aug 02
Moberg Pharma AB Announces That Mob-015 Has Receives National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults Moberg Pharma AB announces that MOB-015 has received national approval in Ireland for the treatment of mild to moderate fungal infections of the nails in adults. Ireland is the first country to grant market authorization for Moberg Pharma's new onychomycosis treatment after the Decentralized Procedure concluded with a positive outcome, where MOB-015 was recommended for national approval in 13 European countries, see press release from June 28th 2023. The Decentralized Procedure includes the following EU countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Currently, national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable, is ongoing. National approvals are expected to follow during upcoming months and timelines may vary between countries. Board Change • Aug 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 5 experienced directors. No highly experienced directors. Independent Director Nikolaj Sorensen is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 06
Moberg Pharma AB (publ) Announces Approval for Mob-015 in the European Union Cipher Pharmaceuticals Inc. announced that the Company's partner, Moberg Pharma AB, has obtained European Union approval for MOB-015 (nail fungus treatment) as a result of demonstrating superior levels of mycological cure (76% vs. 42% for comparators) and a significantly better complete cure rate. MOB-015 has been recommended for national approval in 13 European countries, which will be commercialized through partners such as Bayer and Allderma, and is expected to be launched in Nordic countries such as Sweden during 2023. Cipher holds the exclusive Canadian rights to MOB-015, a new topical treatment of Onychomycosis (nail fungus) based on Moberg's patented proprietary formulation of terbinafine. In Canada, according to IQVIA, the total prescription market for Onychomycosis was greater than $82 million at December 31, 2022 with a single product having over 90% market share. Moberg Pharma continues to invest and advance MOB-015 through an additional phase 3 trial of a total of 350 patients with sites across the United States and Canada. The purpose of this study is to facilitate market approval in North America as well as further strengthen the product's clinical evidence beyond the mycological and complete cure rates already demonstrated to the European Union. Patient enrollment in the clinical trial is progressing according to plan with full enrollment expected in 2023. Announcement • Jun 29
Moberg Pharma AB (Publ) Recommends for Approval in EU Moberg Pharma AB announced that the Decentralized Procedure hasended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults. The approval in the European Union represents the first marketing authorizations for MOB-015's new onychomycosis treatment worldwide. Approval is supported by two Phase 3 trials where MOB-015 demonstrated superior levels of mycological cure (76% vs up to 42% for comparators), and a significantly better complete cure rate compared to vehicle, without any serious adverse reactions. MOB-015 is a topical formulation of terbinafine, enabling effective concentrations of terbinafine to the nail and nail bed while avoiding the risk of systemic exposure seen with oral terbinafine use. The Decentralized Procedure includes the following EU countries: Austria, Belgium, Czech Republic, Denmark, Finland, France, Hungary, Ireland, Italy, Netherlands, Norway, Spain and Sweden. Next steps include national implementation in each country and granting of marketing authorizations including OTC-approvals when applicable. National approvals are expected to follow during upcoming months and timelines may vary between countries. Announcement • May 17
Moberg Pharma AB (Publ) Elects Håkan Wallin to the Board Members Moberg Pharma AB (publ) announced at annual general meeting held on May 16, 2023, the shareholders elected Håkan Wallin as board members for a period until the end of the next Annual General Meeting. Board Change • Sep 26
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Mattias Klintemar was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Aug 25
Moberg Pharma AB (publ) to Report First Half, 2023 Results on Aug 15, 2023 Moberg Pharma AB (publ) announced that they will report first half, 2023 results on Aug 15, 2023